Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is ending 2025 with something investors in AI-driven biotech rarely get in the same month: fresh clinical momentum, a high-profile Wall Street upgrade, and renewed attention from Cathie Wood’s ARK funds—all playing out during a